Peng-Hui Wang

42PUBLICATIONS
73CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Aerospace materialsPredictive and prognostic markersRadiation therapyMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|May 15, 2026
Is chemo-immunotherapy really beneficial for platinum-resistant ovarian cancer?

|May 04, 2026
α2,3-Sialyltransferase (ST3Gal1) regulates endometrioid-type epithelial ovarian cancer cell migration and invasion via VEGF-R2/JAK2/STAT3 signaling cascades.

|Mar 09, 2026
PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan.

Wei-Ting Chao, Yu-Wen Sung, Kuan-Ju Huang

|Mar 02, 2026
Is it safe using organ-sparing surgery in place of complete resection?

Peng-Hui Wang

|Feb 24, 2026
Biomarkers-guidance clinical application is not only for treatment but also for diagnosis.

Peng-Hui Wang

|Nov 10, 2025
Programmed death-ligand 1 upregulation is associated with poor prognosis in patients with epithelial ovarian cancer.

Chia-Hao Liu, Wei-Ting Chao, Szu-Ting Yang

Pageof 7

Frequent Collaborators

7 joint publications

Chia-Hao Liu

3 joint publications

Jae-Weon Kim

3 joint publications

Ching-Hsuan Chen

3 joint publications

Yi-Cheng Wu